CompletedPHASE2, PHASE3NCT04488419

ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

Studying Early-onset autosomal dominant Alzheimer disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
LeonaBio
Principal Investigator
Javier San Martin, MD
Chief Medical Officer
Intervention
ATH-1017(drug)
Enrollment
554 target
Eligibility
55-85 years · All sexes
Timeline
20202024

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04488419 on ClinicalTrials.gov

Other trials for Early-onset autosomal dominant Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for Early-onset autosomal dominant Alzheimer disease

← Back to all trials